Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab with carboplatin and nab-paclitaxel within its marketing authorisation for untreated advanced non-squamous non-small-cell lung cancer.
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
 
Status Suspended
Process STA 2018
ID number 1513

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
11 March 2019 Suspended, As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
18 February 2019 The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope which closed on 06 February 2019. The company developing atezolizumab has advised NICE that they do not intend to participate in a Technology Appraisal for this topic. In light of this information NICE will not be progressing with the scoping exercise. If you have any comments or concerns please contact the Project Manager for this appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance